Giedriaus Mačėno terapija - Company finances
|
EUR
|
2019
From: 2019-10-30
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 290 | 18,030 | 23,890 | 20,389 | 17,793 | 24,384 | 26,562 |
| Profit before tax | -649 | -1,432 | -5,236 | -1,411 | -769 | -1,701 | 454 |
| Net profit | -649 | -1,432 | -5,236 | -1,411 | -769 | -1,701 | 454 |
| Equity | 16,341 | 14,909 | 10,013 | 8,602 | 7,832 | 5,328 | 5,285 |
| Liabilities | - | - | - | 0 | 0 | 0 | 0 |
| Non-current assets | 7,725 | 6,769 | 7,181 | 6,736 | 5,273 | 4,153 | 3,106 |
| Current assets | 8,616 | 8,140 | 2,832 | 1,866 | 2,559 | 1,175 | 2,179 |
| Total assets | 16,341 | 14,909 | 10,013 | 8,602 | 7,832 | 5,328 | 5,285 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | - | 1,518 | 1,574 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +6117.2% | +32.5% | -14.7% | -12.7% | +37.0% | +8.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -4.0% | -9.6% | -52.3% | -16.4% | -9.8% | -31.9% | 8.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -4.0% | -9.6% | -52.3% | -16.4% | -9.8% | -31.9% | 8.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -223.8% | -7.9% | -21.9% | -6.9% | -4.3% | -7.0% | 1.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -223.8% | -7.9% | -21.9% | -6.9% | -4.3% | -7.0% | 1.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Giedriaus Mačėno terapija - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-05-15 | 2024-05-31 | 47.89 |
Giedriaus Mačėno terapija - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Giedriaus Mačėno terapija is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-06-26 | 2026-09-02 | 0.2 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Giedriaus Maceno terapija, MB (code 305270942) is a small partnership engaged in physiotherapy activities. In 2025, the company generated revenue of €26.6K, up 8.9% year on year and 49.3% over two years. Net profit turned positive at €454, after net losses of €1.7K in 2024 and €769 in 2023, indicating a return to profitability. The 2025 profit margin was 1.7%, which remains modest but improved materially from the negative margins reported in the two prior years. The balance sheet remained compact, with total assets and equity both at €5.3K, indicating an equity-financed structure. Within assets, long-term assets amounted to €3.1K and short-term assets to €2.2K. Key efficiency indicators for 2025 were strong relative to the company’s asset base, with asset turnover at 5.03x, ROE at 8.6% and ROA at 8.6%. Overall, the latest year shows revenue growth and a shift from losses to a small profit.